Triveni Bio Inc. has announced a $92 million series A financing that will support the advancement of its lead antibody program, TRIV-509, from preclinical development to a phase IIa clinical trial in atopic dermatitis and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.
Researchers from Shanghai Jiao Tong University and affiliated organizations presented data from a study that aimed to identify new pathogenic genes for autosomal dominant hypotrichosis (hair loss).
Apogee Therapeutics Inc. recently presented preclinical data on its lead candidate, APG-777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of atopic dermatitis and asthma.
In what TD Cowen analyst Joseph Thome called an “upside surprise,” Anaptysbio Inc. reported positive top-line data from its phase III Gemini-1 study of imsidolimab, a monoclonal antibody designed to inhibit the interleukin-36 receptor, in patients with generalized pustular psoriasis (GPP), positioning the firm for a potentially productive out-licensing deal.
Psoriasis is an autoimmune disorder characterized by abnormal differentiation of keratinocytes and chronic inflammation where current treatments frequently are associated with severe side effects.
Leo Pharma A/S researchers have synthesized new interleukin-17 (IL-17) modulators reported to be useful for the treatment of psoriasis, psoriatic arthritis, spondyloarthritis, radiographic ankylosing spondylitis (ankylosing spondylitis) and autoimmune diseases.
Di-cyclopropyl based interleukin-17A (IL-17A) production inhibitors have been reported in a Dice Alpha Inc. patent as potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.
Scinai Immunotherapeutics Ltd. (formerly Biondvax Pharmaceuticals Ltd.) has released promising results from a preclinical study of Scinai’s anti‑IL‑17 nanosized VHH antibodies (NanoAbs) as a treatment for plaque psoriasis. The alpaca‑derived recombinant variable domain of heavy-chain-only antibodies are designed to be administered locally.
Acelyrin Inc.’s shares tumbled after its interleukin-17A inhibitor, izokibep, failed to reachstatistical significance in part B of a phase IIb/III trial inmoderate to severe hidradenitis suppurativa (HS), but the company remains undeterred with its plans to advance the drug for the inflammatory skin condition.
RSS
